(Q44388370)

2 December 2017

A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study (English)

1 reference

2 December 2017

Miklya I

1

1 reference

2 December 2017

Knoll B

series ordinal

2

1 reference

2 December 2017

Knoll J

series ordinal

3

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

2 December 2017

1 reference

2 December 2017

72

1 reference

2 December 2017

2641-2648

1 reference

2 December 2017

23

1 reference

(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

Effect of deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900174-7

10.1016/S0024-3205(03)00174-7

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference